Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2022

04.01.2022 | Original Article

Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia

verfasst von: Eugene Kligman, Hiba Ali, Ellie Chen, Frederick Peng, David Szafron, Kristen Staggers, Mimi C. Tan, Kalpesh Patel, Mohamed O. Othman

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Gastric intestinal metaplasia (GIM) is a precursor to gastric adenocarcinoma, making it an attractive target for early detection by endoscopy. The aim of this study was to determine the prevalence, risk factors, and associated histologic findings of GIM among patients undergoing endoscopy in a diverse US population.

Methods

We conducted a retrospective, cross-sectional study of patients undergoing elective endoscopy with gastric biopsies at 6 academic and community centers in Houston, Texas. GIM prevalence was estimated with a 95% confidence interval (CI), and patient demographic and clinical characteristics were summarized using mean with standard deviation, or frequency with percentage. Generalized estimating equations (GEE) were used to compare characteristics between those with and without GIM.

Results

Our final cohort consisted of 2685 patients, including 216 cases with GIM and 2469 controls. The prevalence of GIM in our cohort was 8.04% (95% CI 7.07%, 9.14%). The mean age of GIM cases was higher than in the control group (59.8 vs 54.7 years, p < 0.0001). The prevalence of GIM in Asians, Hispanic, Black and Non-Hispanic Whites (NHW) was 14.7%, 11.7%, 9.8% and 5.8%, respectively. On multivariable analysis, factors associated with GIM include age (adj. OR 1.32 per 10 year increase, p < 0.0001), habitual smoking (adj. OR 1.68, p < 0.0001), and race (compared to NHW: Asian, adj. OR 2.34, p = 0.010; Hispanic, adj. OR 2.15, p < 0.001; Black, adj. OR 1.61, p < 0.001).

Conclusion

Asians, Hispanics, and African Americans have higher rates of GIM than NHW. Ethnicity should be an important consideration on determining who to screen for GIM in the US.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef
2.
Zurück zum Zitat Jencks DS, Adam JD, Borum ML et al. Overview of current concepts in gastric intestinal metaplasia and gastric cancer. Gastroenterol Hepatol (NY) 2018;14:92–101. Jencks DS, Adam JD, Borum ML et al. Overview of current concepts in gastric intestinal metaplasia and gastric cancer. Gastroenterol Hepatol (NY) 2018;14:92–101.
3.
Zurück zum Zitat Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.PubMed Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.PubMed
4.
Zurück zum Zitat Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef
5.
Zurück zum Zitat Correa P. Gastric cancer: overview. Gastroenterol Clin N Am 2013;42:211–217.CrossRef Correa P. Gastric cancer: overview. Gastroenterol Clin N Am 2013;42:211–217.CrossRef
6.
Zurück zum Zitat Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25–40.CrossRef Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25–40.CrossRef
7.
Zurück zum Zitat de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.CrossRef de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.CrossRef
8.
Zurück zum Zitat Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol 2016;111:1104–1113.CrossRef Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol 2016;111:1104–1113.CrossRef
9.
Zurück zum Zitat Shaheen NJ, Falk GW, Iyer PG et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.CrossRef Shaheen NJ, Falk GW, Iyer PG et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.CrossRef
10.
Zurück zum Zitat Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018;155:347-354.e9.CrossRef Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018;155:347-354.e9.CrossRef
11.
Zurück zum Zitat Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158:693–702.CrossRef Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158:693–702.CrossRef
12.
Zurück zum Zitat Haastrup PF, Jarbol DE, Thompson W et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563.CrossRef Haastrup PF, Jarbol DE, Thompson W et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563.CrossRef
13.
Zurück zum Zitat Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894-1901.e2.CrossRef Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894-1901.e2.CrossRef
14.
Zurück zum Zitat Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an underserved population in the USA: prevalence, epidemiologic and clinical features. Gastroenterol Res Pract 2013;2013:856256.CrossRef Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an underserved population in the USA: prevalence, epidemiologic and clinical features. Gastroenterol Res Pract 2013;2013:856256.CrossRef
15.
Zurück zum Zitat Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef
16.
Zurück zum Zitat Choi AY, Strate LL, Fix MC et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a US population. Gastrointest Endosc 2018;87:1023–1028.CrossRef Choi AY, Strate LL, Fix MC et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a US population. Gastrointest Endosc 2018;87:1023–1028.CrossRef
17.
Zurück zum Zitat Kim N, Park YS, Cho SI et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–255.CrossRef Kim N, Park YS, Cho SI et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–255.CrossRef
18.
Zurück zum Zitat Lee TY, Wang RC, Lee YC et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: a long-term cohort study. J Clin Gastroenterol 2016;50:532–537.CrossRef Lee TY, Wang RC, Lee YC et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: a long-term cohort study. J Clin Gastroenterol 2016;50:532–537.CrossRef
19.
Zurück zum Zitat Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169–1179.CrossRef Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169–1179.CrossRef
20.
Zurück zum Zitat Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249.CrossRef Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249.CrossRef
21.
Zurück zum Zitat Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.CrossRef Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.CrossRef
22.
Zurück zum Zitat Chen HN, Wang Z, Li X et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166–175.CrossRef Chen HN, Wang Z, Li X et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166–175.CrossRef
23.
Zurück zum Zitat Kneller RW, You WC, Chang YS et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261–1266.CrossRef Kneller RW, You WC, Chang YS et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261–1266.CrossRef
25.
Zurück zum Zitat Morais S, Rodrigues S, Amorim L et al. Tobacco smoking and intestinal metaplasia: systematic review and meta-analysis. Dig Liver Dis 2014;46:1031–1037.CrossRef Morais S, Rodrigues S, Amorim L et al. Tobacco smoking and intestinal metaplasia: systematic review and meta-analysis. Dig Liver Dis 2014;46:1031–1037.CrossRef
26.
Zurück zum Zitat Pittayanon R, Rerknimitr R, Klaikaew N et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther 2017;46:40–45.CrossRef Pittayanon R, Rerknimitr R, Klaikaew N et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther 2017;46:40–45.CrossRef
27.
Zurück zum Zitat Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319–326.CrossRef Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319–326.CrossRef
28.
Zurück zum Zitat Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014;2014:CD010623. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014;2014:CD010623.
29.
Zurück zum Zitat Saumoy M, Schneider Y, Shen N et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef Saumoy M, Schneider Y, Shen N et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef
30.
Zurück zum Zitat Kim SG, Park CM, Lee NR et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. Gut Liver 2018;12:402–410.CrossRef Kim SG, Park CM, Lee NR et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. Gut Liver 2018;12:402–410.CrossRef
Metadaten
Titel
Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia
verfasst von
Eugene Kligman
Hiba Ali
Ellie Chen
Frederick Peng
David Szafron
Kristen Staggers
Mimi C. Tan
Kalpesh Patel
Mohamed O. Othman
Publikationsdatum
04.01.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07326-2

Weitere Artikel der Ausgabe 9/2022

Digestive Diseases and Sciences 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.